A comparison of rheumatoid arthritis and systemic lupus erythematosus trial design: A commentary on ways to improve the number of positive trials in SLE

Clinical and Experimental Rheumatology

Volumn 33, Issue 5, 2015, Pages 671-680

  Miles, Amy ^a   Pope, Janet E ^b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b WESTERN UNIVERSITY   (Canada)

^c ST JOSEPH S HEALTH CENTRE   (Canada)

Author keywords

Lupus; Rheumatoid arthritis; Systemic lupus erythematosus; Trial design

Indexed keywords

ABATACEPT; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; BELIMUMAB; CORTICOSTEROID; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DOUBLE STRANDED DNA ANTIBODY; EPRATUZUMAB; GOLIMUMAB; METHOTREXATE; MYCOPHENOLATE MOFETIL; PLACEBO; PREDNISOLONE; PREDNISONE; RHEUMATOID FACTOR; RITUXIMAB; TOCILIZUMAB; IMMUNOSUPPRESSIVE AGENT;

ACR20 MEASUREMENT; ACR50 MEASUREMENT; ARTICLE; BILAG BASED COMPOSITE LUPUS ASSESSMENT; BRITISH ISLES LUPUS ASSESSMENT GROUP; COMPARATIVE STUDY; DAS28; DISEASE ACTIVITY; DISEASE EXACERBATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RHEUMATOID ARTHRITIS; SAMPLE SIZE; SELENA SLEDAI; SLE ACTIVITY MEASUREMENT SCORE; SLE RESPONDER INDEX; SLEDAI; STUDY DESIGN; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT FAILURE; TREATMENT RESPONSE; ARTHRITIS, RHEUMATOID; BIOASSAY; DRUG COMBINATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; METHODOLOGY; PATIENT SELECTION; PROCEDURES; TIME; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; ENDPOINT DETERMINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; RESEARCH DESIGN; SAMPLE SIZE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84944383925     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. COHEN SB, EMERY P, GREENWALD MW et al.: Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results: of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793-806.
2. EMERY P, DEODHAR A, RIGBY WF et al.: Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis 2010; 69: 1629-35.
3. TAK PP, RIGBY WF, RUBBERT-ROTH A et al.: Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 2011; 70: 39-46.
4. MEASE PJ, COHEN S, GAYLIS NB et al.: Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial. J Rheumatol 2010; 37: 917-27.
5. EMERY P, FLEISCHMANN R, FILIPOWICZSOSNOWSKA A et al.: The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, doubleblind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006; 54: 1390-400.
6. ALBERT D, DUNHAM J, KHAN S et al.: Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann Rheum Dis 2008; 67: 1724-31.
7. LINDHOLM C, BORJESSON-ASP K, ZENDJANCHI K et al.: Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol 2008; 35: 826-33.
8. PODOLSKAYA A, STADERMANN M, PILKINGTON C, MARKS SD, TULLUS K: B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus. Arch Dis Child 2008; 93: 401-06.
9. MERRILL JT, NEUWELT CM, WALLACE DJ et al.: Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, doubleblind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62: 222-33.
10. ROVIN BH, FURIE R, LATINIS K et al.: Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012; 64: 1215-26.
11. MERRILL JT, BURGOS-VARGAS R, WESTHOVENS R et al.: The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010; 62: 3077-87.
12. FURIE R, PETRI M, ZAMANI O et al.: A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011; 63: 3918-30.
13. NAVARRA SV, GUZMAN RM, GALLACHER AE et al.: Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 721-31.
14. STONE JH: BLISS! Lupus learns its lessons. Lancet 2011; 377: 693-94.
15. LUIJTEN KM, TEKSTRA J, BIJLSMA JW, BIJL M: The Systemic Lupus Erythematosus Responder Index (SRI); a new SLE disease activity assessment. Autoimmun Rev 2012; 11: 326-29.
16. WALLACE DJ, STOHL W, FURIE RA et al.: A phase II, randomized, double-blind, placebocontrolled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009; 61: 1168-78.
17. FORTIN PR, ABRAHAMOWICZ M, FERLAND D et al.: Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2008; 59: 1796-804.
18. WALLACE DJ, GORDON C, STRAND V et al.: Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Rheumatology (Oxford) 2013; 52: 1313-22.
19. WALLACE DJ, KALUNIAN K, PETRI MA et al.: Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis 2013.
20. SMOLEN JS, KAY J, DOYLE MK et al.: Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009; 374: 210-21.
21. NISHIMOTO N, MIYASAKA N, YAMAMOTO K et al.: Study of active controlled tocilizumabmonotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009; 19: 12-19.
22. JONES G, SEBBA A, GU J et al.: Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010; 69: 88-96.
23. KREMER JM, BLANCO R, BRZOSKO M et al.: Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011; 63: 609-21.
24. KREMER JM, GENANT HK, MORELAND LW et al.: Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006; 144: 865-76.
25. WESTHOVENS R, ROBLES M, XIMENES AC et al.: Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 2009; 68: 1870-77.
26. YAZICI Y, CURTIS JR, INCE A et al.: Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Ann Rheum Dis 2012; 71: 198-205.
27. GENOVESE MC, McKAY JD, NASONOV EL et al.: Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008; 58: 2968-80.
28. EMERY P, KEYSTONE E, TONY HP et al.: IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebocontrolled trial. Ann Rheum Dis 2008; 67: 1516-23.
29. SMOLEN JS, BEAULIEU A, RUBBERT-ROTH A et al.: Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a doubleblind, placebo-controlled, randomised trial. Lancet 2008; 371: 987-97.
30. MAINI RN, TAYLOR PC, SZECHINSKI J et al.: Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006; 54: 2817-29.
31. KEYSTONE E, EMERY P, PETERFY CG et al.: Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis 2009; 68: 216-21.
32. STOHL W, MERRILL JT, McKAY JD et al.: Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging Study. J Rheumatol 2013; 40: 579-89.
33. TANAKA Y, HARIGAI M, TAKEUCHI T et al.: Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study. Ann Rheum Dis 2012; 71: 817-24.
34. KAY J, MATTESON EL, DASGUPTA B et al.: Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2008; 58: 964-75.
35. GENOVESE MC, BECKER JC, SCHIFF M et al.: Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005; 353: 1114-23.
36. WEINBLATT ME, BINGHAM CO 3RD, MENDELSOHN AM et al.: Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, doubleblind, placebo-controlled GO-FURTHER trial. Ann Rheum Dis 2013; 72: 381-89.
37. JONES G: The AMBITION trial: tocilizumab monotherapy for rheumatoid arthritis. Expert Rev Clin Immunol 2010; 6: 189-95.
38. DöRNER T, KAUFMANN J, WEGENER WA, TEOH N, GOLDENBERG DM, BURMESTER GR: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006; 8: R74.
39. SMOLEN JS, KAY J, LANDEWé RB et al.: Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160. Ann Rheum Dis 2012; 71: 1671-79.
40. CHATZIDIONYSIOU K, LIE E, NASONOV E et al.: Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis 2011; 70: 1575-80.
41. ABUD-MENDOZA C, MORENO-VALDéS R, CUEVAS-ORTA E et al.: Treating severe systemic lupus erythematosus with rituximab. An open study. Reumatol Clin 2009; 5:147-52.
42. MEASE PJ, REVICKI DA, SZECHINSKI J et al.: Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results: of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial. J Rheumatol 2008; 35: 20-30.
43. YUEN SY, POPE JE: Learning from past mistakes: assessing trial quality, power and eligibility in non-renal systemic lupus erythematosus randomized controlled trials. Rheumatology (Oxford) 2008; 47: 1367-72.
44. FELSON DT, ANDERSON JJ, BOERS M et al.: American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
45. POPE JE, KHANNA D, NORRIE D, OUIMET JM: The minimally important difference for the health assessment questionnaire in rheumatoid arthritis clinical practice is smaller than in randomized controlled trials. J Rheumatol 2009; 36: 254-59.
46. KHANNA D, POPE JE, KHANNA PP et al.: The minimally important difference for the fatigue visual analog scale in patients with rheumatoid arthritis followed in an academic clinical practice. J Rheumatol 2008; 35: 2339-43.
47. COLANGELO KJ, POPE JE, PESCHKEN C: The minimally important difference for patient reported outcomes in systemic lupus erythematosus including the HAQ-DI, pain, fatigue, and SF-36. J Rheumatol 2009; 36: 2231-37.
48. BRUNNER HI, GLADMAN DD, IBAñEZ D, UROWITZ MD, SILVERMAN ED: Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum 2008; 58: 556-62.
49. RUPERTO N, RAVELLI A, CUTTICA R et al.: The Pediatric Rheumatology International Trials Organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the disease activity core set. Arthritis and Rheumatism 2005; 52: 2854-64.
50. RUPERTO N, RAVELLI A, OLIVEIRA S et al.: The Pediatric Rheumatology International Trials Organization/American College of Rheumatology provisional criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the definition of improvement. Arthritis Rheum 2006; 55: 355-63.
51. MINA R, KLEIN-GITELMAN MS, NELSON S et al.: Validation of the systemic lupus erythematosus responder index for use in juvenileonset systemic lupus erythematosus. Ann Rheum Dis 2014; 73: 401-6.
52. TOUMA Z, GLADMAN DD, IBAñEZ D, UROWITZ MB: Development and initial validation of the systemic lupus erythematosus disease activity index 2000 responder index 50. J Rheumatol 2011; 38: 275-84.
53. TOUMA Z, GLADMAN DD, IBAñEZ D, TAGHAVI-ZADEH S, UROWITZ MB: Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 enhances the ability of SLE Responder Index to identify responders in clinical trials. J Rheumatol 2011; 38: 2395-99.
54. DALL'ERA M, WOFSY D: Systemic lupus erythematosus clinical trials-an interim analysis. Nat Rev Rheumatol 2009; 5: 348-51.
55. FAVALLI EG, BIGGIOGGERO M, PREGNOLATO F et al.: Disease duration and year of publication affect the results of studies on rheumatoid arthritis damage progression by biologic agents: A systematic review and metaanalysis. EULAR 2013; 2013: 214.